Citadel Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-68,600
| Closed | -$2.76M | – | 13640 |
|
|
2026
Q1 | $2.76M | Sell |
68,600
-55,400
| -45% | -$1.19M | ﹤0.01% | 5434 |
|
|
2025
Q4 | $3.11M | Buy |
124,000
+10,200
| +9% | +$239K | ﹤0.01% | 5086 |
|
|
2025
Q3 | $2.58M | Buy |
113,800
+39,500
| +53% | +$921K | ﹤0.01% | 5576 |
|
|
2025
Q2 | $1.29M | Sell |
74,300
-14,200
| -16% | -$263K | ﹤0.01% | 6559 |
|
|
2025
Q1 | $1.94M | Sell |
88,500
-45,400
| -34% | -$1.25M | ﹤0.01% | 5596 |
|
|
2024
Q4 | $4.27M | Sell |
133,900
-47,200
| -26% | -$1.42M | ﹤0.01% | 4216 |
|
|
2024
Q3 | $5.22M | Buy |
181,100
+8,800
| +5% | +$326K | ﹤0.01% | 3869 |
|
|
2024
Q2 | $6.61M | Sell |
172,300
-120,700
| -41% | -$5.47M | ﹤0.01% | 3333 |
|
|
2024
Q1 | $17.2M | Sell |
293,000
-115,400
| -28% | -$7.36M | ﹤0.01% | 2239 |
|
|
2023
Q4 | $24.4M | Buy |
408,400
+99,900
| +32% | +$5.07M | ﹤0.01% | 1815 |
|
|
2023
Q3 | $11.7M | Buy |
308,500
+92,900
| +43% | +$4.08M | ﹤0.01% | 2481 |
|
|
2023
Q2 | $19.6M | Buy |
215,600
+28,700
| +15% | +$2.48M | ﹤0.01% | 1903 |
|
|
2023
Q1 | $12.3M | Sell |
186,900
-8,800
| -4% | -$508K | ﹤0.01% | 2528 |
|
|
2022
Q4 | $10.1M | Buy |
195,700
+101,500
| +108% | +$5.38M | ﹤0.01% | 2828 |
|
|
2022
Q3 | $6.43M | Buy |
94,200
+30,300
| +47% | +$1.79M | ﹤0.01% | 3454 |
|
|
2022
Q2 | $2.89M | Sell |
63,900
-15,100
| -19% | -$688K | ﹤0.01% | 4823 |
|
|
2022
Q1 | $4.01M | Buy |
79,000
+17,500
| +28% | +$773K | ﹤0.01% | 4601 |
|
|
2021
Q4 | $2.91M | Sell |
61,500
-262,600
| -81% | -$10.3M | ﹤0.01% | 5400 |
|
|
2021
Q3 | $10.7M | Buy |
324,100
+235,200
| +265% | +$13.2M | ﹤0.01% | 2965 |
|
|
2021
Q2 | $5.62M | Buy |
88,900
+60,200
| +210% | +$3.11M | ﹤0.01% | 4183 |
|
|
2021
Q1 | $1.23M | Buy |
28,700
+16,900
| +143% | +$800K | ﹤0.01% | 7577 |
|
|
2020
Q4 | $675K | Sell |
11,800
-100
| -0.8% | -$4.23K | ﹤0.01% | 7566 |
|
|
2020
Q3 | $359K | Sell |
11,900
-41,300
| -78% | -$1.23M | ﹤0.01% | 7833 |
|
|
2020
Q2 | $1.74M | Sell |
53,200
-70,900
| -57% | -$2.28M | ﹤0.01% | 4821 |
|
|
2020
Q1 | $3.33M | Buy |
124,100
+64,400
| +108% | +$2.29M | ﹤0.01% | 3298 |
|
|
2019
Q4 | $1.83M | Buy |
+59,700
| New | +$1.65M | ﹤0.01% | 4556 |
|
Other funds holding APLS
Citadel Advisors's APLS Position: Q2 2026 in Review
Citadel Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 38,887 shares — an estimated $1.56M sold.
Citadel Advisors first reported a position in APLS in Q2 2018 and held it in 31 quarters. The position peaked at $82.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Citadel Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 38,887 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.56M.
- Citadel Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 31 quarters.
- Citadel Advisors's Apellis Pharmaceuticals position peaked at $82.2M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.